Is Afatinib used for lung Cancer?
Afatinib is an irreversibly binding second-generation EGFR tyrosine kinase inhibitor developed by Boehringer Ingelheim. It was first approved for marketing by the U.S. FDA on July 12, 2013, and then approved by the EMA for the treatment of advanced non-small cell lung cancer with EGFR sensitive mutations. In March and April 2016, it was approved by the EMA and FDA respectively to add the indication of "squamous histology non-small cell lung cancer that has failed platinum-containing chemotherapy.
Read More- https://www.medixocentre.com/afatinib-cost
پسندیدن
اظهار نظر
اشتراک گذاری
